Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Gross Margin (2016 - 2025)

Arcadia Biosciences' Gross Margin history spans 12 years, with the latest figure at 21.31% for Q4 2025.

  • For Q4 2025, Gross Margin fell 1068.0% year-over-year to 21.31%; the TTM value through Dec 2025 reached 36.21%, down 507.0%, while the annual FY2025 figure was 36.23%, 504.0% down from the prior year.
  • Gross Margin reached 21.31% in Q4 2025 per RKDA's latest filing, down from 32.1% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 115.49% in Q4 2022 to a low of 7.39% in Q1 2022.
  • Average Gross Margin over 5 years is 38.35%, with a median of 34.92% recorded in 2023.
  • Peak YoY movement for Gross Margin: surged 53006bps in 2021, then plummeted -8916bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 12.7% in 2021, then surged by 809bps to 115.49% in 2022, then tumbled by -33bps to 77.09% in 2023, then tumbled by -59bps to 31.99% in 2024, then crashed by -33bps to 21.31% in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Gross Margin are 21.31% (Q4 2025), 32.1% (Q3 2025), and 43.37% (Q2 2025).